Katherine Hannan

The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer

Shunfei Yan, Jiachen Xuan, Natalie Brajanovski, Madeleine RC Tancock, Piyush B Madhamshettiwar, Kaylene J Simpson, Sarah Ellis, Jian Kang, Carleen Cullinane, Karen E Sheppard, Katherine M Hannan, Ross D Hannan, Elaine Sanij, Richard B Pearson, Keefe T Chan

Journal article  |  2020  |  British Journal of Cancer

BACKGROUND: Intrinsic and acquired drug resistance represent fundamental barriers to the cure of high-grade serous ovarian carcino..

Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis

Eric P Kusnadi, Anna S Trigos, Carleen Cullinane, David L Goode, Ola Larsson, Jennifer R Devlin, Keefe T Chan, David P De Souza, Malcolm J McConville, Grant A McArthur, George Thomas, Elaine Sanij, Gretchen Poortinga, Ross D Hannan, Katherine M Hannan, Jian Kang, Richard B Pearson

Journal article  |  2020  |  The EMBO Journal

Elevated ribosome biogenesis in oncogene-driven cancers is commonly targeted by DNA-damaging cytotoxic drugs. Our previous first-i..

Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression

Jixuan Gao, MoonSun Jung, Chelsea Mayoh, Pooja Venkat, Katherine M Hannan, Jamie Fletcher, Alvin Kamili, Andrew J Gifford, Eric P Kusnadi, Richard B Pearson, Ross D Hannan, Michelle Haber, Murray D Norris, Klaartje Somers, Michelle J Henderson

Journal article  |  2020  |  Cancer Research

The ability of the N-MYC transcription factor to drive cancer progression is well demonstrated in neuroblastoma, the most common e..

Harnessing the self-assembly of peptides for the targeted delivery of anti-cancer agents

Stephanie J Franks, Kate Firipis, Rita Ferreira, Katherine M Hannan, Richard J Williams, Ross D Hannan, David R Nisbet

Journal article  |  2020  |  Materials Horizons

rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461

Jinbae Son, Katherine M Hannan, Gretchen Poortinga, Nadine Hein, Donald P Cameron, Austen RD Ganley, Karen E Sheppard, Richard B Pearson, Ross D Hannan, Elaine Sanij

Journal article  |  2020  |  Frontiers in Cell and Developmental Biology

Hyperactivation of RNA polymerase I (Pol I) transcription of ribosomal RNA (rRNA) genes (rDNA) is a key determinant of growth and ..

Abstract PR13: Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer

Elaine Sanij, Katherine Hannan, Jiachen Xuan, Shunfei Yan, Jessica A Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A McArthur, John Soong, Els M Berns, et al.

Conference Proceedings  |  2020  |  Oral Presentations - Proffered Abstracts

Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer.

Elaine Sanij, Katherine Hannan, Jiachen Xuan, Shunfei Yan, Jessica A Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A McArthur, John Soong, Els M Berns, et al.

Journal article  |  2020  |  CLINICAL CANCER RESEARCH

Abstract High-grade serous ovarian cancer (HGSOC) accounts for the majority of ovarian cancer and has a dismal prognosis. PARP inh..

Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer.

Elaine Sanij, Katherine Hannan, Jiachen Xuan, Shunfei Yan, Jessica A Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A McArthur, John Soong, Els M Berns, et al.

Conference Proceedings  |  2020  |  Clinical Cancer Research

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Elaine Sanij, Katherine M Hannan, Jiachen Xuan, Shunfei Yan, Jessica E Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Daniel Frank, Sarah Ellis, Carleen Cullinane, Jian Kang, Gretchen Poortinga, Purba Nag, Andrew J Deans, Kum Kum Khanna, et al.

Journal article  |  2020  |  NATURE COMMUNICATIONS

Acquired resistance to PARP inhibitors (PARPi) is a major challenge for the clinical management of high grade serous ovarian cance..

PGRMC1 phosphorylation affects cell shape, motility, glycolysis, mitochondrial form and function, and tumor growth

Bashar M Thejer, Partho P Adhikary, Amandeep Kaur, Sarah L Teakel, Ashleigh Van Oosterum, Ishith Seth, Marina Pajic, Katherine M Hannan, Megan Pavy, Perlita Poh, Jalal A Jazayeri, Thiri Zaw, Dana Pascovici, Marina Ludescher, Michael Pawlak, Juan C Cassano, Lynne Turnbull, Mitra Jazayeri, Alexander C James, Craig P Coorey, et al.

Journal article  |  2020  |  BMC Molecular and Cell Biology

BACKGROUND: Progesterone Receptor Membrane Component 1 (PGRMC1) is expressed in many cancer cells, where it is associated with det..